Inscription Capital LLC purchased a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 21,819 shares of the company's stock, valued at approximately $303,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TAK. FNY Investment Advisers LLC bought a new stake in shares of Takeda Pharmaceutical during the first quarter valued at approximately $37,000. Farther Finance Advisors LLC increased its holdings in Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after buying an additional 1,976 shares during the period. Crowley Wealth Management Inc. bought a new stake in Takeda Pharmaceutical in the 4th quarter valued at $52,000. Cromwell Holdings LLC bought a new stake in Takeda Pharmaceutical in the 4th quarter valued at $61,000. Finally, Venturi Wealth Management LLC increased its holdings in Takeda Pharmaceutical by 554.7% in the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after buying an additional 4,260 shares during the period. 9.17% of the stock is currently owned by institutional investors.
Takeda Pharmaceutical Price Performance
NYSE TAK traded down $0.16 on Friday, reaching $14.75. The company's stock had a trading volume of 3,413,399 shares, compared to its average volume of 1,954,775. Takeda Pharmaceutical Co. has a 52 week low of $12.78 and a 52 week high of $15.43. The firm has a market cap of $46.92 billion, a PE ratio of 67.03 and a beta of 0.23. The business has a 50-day moving average price of $14.79 and a 200 day moving average price of $14.20. The company has a current ratio of 1.01, a quick ratio of 0.52 and a debt-to-equity ratio of 0.57.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. The company had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. Sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.
Read Our Latest Report on Takeda Pharmaceutical
About Takeda Pharmaceutical
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
See Also
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
